Leveraging Tumour Resistance Models to Empower ADC Development & Overcome Resistance Mechanisms

• Spotlighting the development of predictive preclinical resistance models
• Uncovering mechanistic insights into intrinsic and acquired resistance pathways
• Dissecting efficacy and linker properties using these models to improve the clinical translatability of ADC therapies

Speakers:

Manel Merabet

Chief Development Officer

SKYMAB Biotherapeutics